36
Participants
Start Date
April 24, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
October 31, 2025
Tazarotene (GRI-0621)
Oral 4.5mg soft gel capsule
Placebo
Oral 4.5mg soft gel capsule
Concord General Repatriation Hospital, Concord
St. George Hospital, Kogarah
The Canberra Hospital, Garran
Montefiore Medical Center, The Bronx
Southeastern Research Center, Winston-Salem
MUSC Pulmonary Research, Charleston
Mayo Clinic, Jacksonville
Newport Native MD, Inc., Newport Beach
Royal Infirmary Edinburgh, Edinburgh
University Hospital Birmingham, Queen Elizabeth Hospital, Birmingham
Royal Papworth Hospital NHS Foundation Trust, Cambridge
Royal Devon and University Healthcare NHS Foundation Trust, Exeter
University College London Hospitals, London
Western Health and Social Care Trust (WHSCT), Londonderry
Norfolk & Norwich University Hospital, Norwich
Oxford University Hospitals NHS Foundation Trust, Oxford
GRI Bio Operations, Inc.
INDUSTRY